VOR (Vor Biopharma) ROCE %: -30.26% (As of Mar. 2026)


VOR Vor Biopharma Inc VOR
32 GF Score
Price $19.14
! 3 Warning Signs
View Full Analysis

What is Vor Biopharma ROCE %?

Vor Biopharma VOR -3.09% 32 ROCE % is -30.26% as of Mar. 2026. GuruFocus rates VOR with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vor Biopharma's annualized ROCE % for the quarter that ended in Mar. 2026 was -30.26%.

Vor Biopharma  (NAS:VOR) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vor Biopharma ROCE % Related Terms

Vor Biopharma ROCE % Historical Data

* Premium members only.

The historical data trend for Vor Biopharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vor Biopharma ROCE % Chart

Vor Biopharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -46.30 -36.02 -53.77 -78.99 -131.97

Vor Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -122.81 -917.40 -73.97 -48.24 -30.26
VOR
32GF Score
Vor Biopharma Inc VOR
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vor Biopharma ROCE % Calculation

Vor Biopharma's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-371.642/( ( (142.891 - 18.612) + (464.126 - 25.171) )/ 2 )
=-371.642/( (124.279+438.955)/ 2 )
=-371.642/281.617
=-131.97 %

Vor Biopharma's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-140.64/( ( (464.126 - 25.171) + (506.746 - 16.077) )/ 2 )
=-140.64/( ( 438.955 + 490.669 )/ 2 )
=-140.64/464.812
=-30.26 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -30.26% mean?
Vor Biopharma (VOR) has a ROCE % of -30.26% as of Mar. 2026.
Is Vor Biopharma's ROCE % too high?
Vor Biopharma's current ROCE % is -30.26%. Overall, Vor Biopharma has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Vor Biopharma's ROCE % compare to ODTX and ANNX?
Vor Biopharma's ROCE % of -30.26% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Vor Biopharma's current ROCE % is -30.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vor Biopharma stock overvalued right now?
Vor Biopharma (VOR) has a current ROCE % of -30.26%. The current ROCE % is -30.26%. Vor Biopharma's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Vor Biopharma (VOR), the current ROCE % is -30.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vor Biopharma Business Description

Address 500 Boylston Street, Suite 1350, Boston, MA, USA, 02116
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
32GF Score

Get the complete analysis for VOR

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.14
Price